NEW OR RETURNING USERS: SIGN IN  |   UPDATE PROFILE  |   CME/CE TRACKER    



  

Infectious Diseases

New Approaches to
Pediatric Skin and
Skin Structure Infections

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Infectious Diseases.

New Approaches to Pediatric Skin and Skin Structure Infections


Skin and skin structure infections account for up to 18% of visits to pediatricians, but their empiric treatment is no longer routine. While Staphylococcus aureus and Streptococcus pyogenes remain the most frequently isolated gram-positive pathogens in uncomplicated skin infections, the increasing prevalence of methicillin-resistant S aureus makes culture and follow-up imperative. Where resistance rates are particularly high, cephalosporins, the most prescribed office antibiotics, will not be effective. Fortunately, some new therapies have been developed that offer promise.

For this reason, experts in dermatology, pediatrics, and microbiology recently convened in Atlanta for 7 mini-symposia, to examine the changing epidemiology of these infections, how to recognize their varying presentation, the selection of topical versus oral therapy, and when to consider hospitalization.

CO-CHAIRS
Ronald N. Jones, MD
President/CEO
JMI Laboratories
North Liberty, IA

George H. McCracken, Jr, MD
Professor of Pediatrics
The University of Texas
Southwestern Medical Center at Dallas
Dallas, TX

FACULTY
Stan L. Block, MD
Professor of Clinical Pediatrics
University of Louisville
Louisville, KY
University of Kentucky
Lexington, KY

John E. McGowan, Jr, MD
Professor
Department of Epidemiology
Rollins School of Public Health
Emory University
Atlanta, GA


Janet R. Casey, MD
Clinical Associate
  Professor of Pediatrics
University of Rochester
  Medical Center
Co-Director of Research
Elmwood Pediatric Group
Rochester, NY

Lawrence C. Parish, MD
Clinical Professor of Dermatology and
  Cutaneous Biology
Director of the Jefferson Center
  for International Dermatology
Jefferson Medical College of
  Thomas Jefferson University
Philadelphia, PA


Gary V. Doern, PhD
Professor of Pathology
University of Iowa
College of Medicine
Iowa City, IA
Michael E. Pichichero, MD
Professor of Microbiology &
  Immunology,
Professor of Pediatrics, and
  Professor of Medicine
University of Rochester School of
  Medicine and Dentistry
Rochester, NY

Candice E. Johnson, MD, PhD
Clinical Professor of Pediatrics
Department of Pediatrics
The Children's Hospital
University of Colorado
  School of Medicine
Denver, CO


top

TARGET AUDIENCE
This activity has been designed for pediatricians and pediatric dermatologists.

ACTIVITY GOAL
The goal of this activity is to educate clinicians about all aspects of uSSSIs and their treatment with various agents, and with methods for minimizing the development of resistance, leading to improved patient outcomes.

LEARNING OBJECTIVES
To view the learning objectives for each of the presentations, please click here.
top

CME INFORMATION

STATEMENT OF ACCREDITATION: PHYSICIANS
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
Projects In Knowledge designates this educational activity for a maximum of 3.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

Assignment of credit for this activity:
Two 15-minute lectures — .25 Category 1 credit each
Five 30-minute lectures — .50 Category 1 credit each

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Stan L. Block, MD, has received grant/research support from Abbott Laboratories; is a consultant for Abbott Laboratories and GlaxoSmithKline; and is on the speakers bureau and advisory board of Abbott Laboratories. Dr. Block has disclosed that he will reference unlabeled/unapproved use of retapamulin for skin infections.

Janet R. Casey, MD, is a consultant for Abbott Laboratories; is on the speakers bureau of Abbott Laboratories and Sanofi-Aventis; and is on the advisory boards of Abbott Laboratories, Advanis, and Sanofi-Aventis. Dr. Casey has disclosed that she will not reference unlabeled/unapproved uses of drugs or devices.

Gary V. Doern, PhD, has received grant/research support from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, and Bayer Pharmaceuticals Corporation; and is on the speakers bureaus of Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Pfizer Inc, and Schering-Plough Corporation. Dr. Doern has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices in this activity.

Candice E. Johnson, MD, PhD, has received grant/research support from Ferndale Labs, GlaxoSmithKline, and Merck & Co, Inc; is a consultant for Merck & Co, Inc; and is on the speakers bureau for Abbott Laboratories, GlaxoSmithKline, and Merck & Co, Inc. Dr. Johnson has disclosed that she will not reference unlabeled or unapproved uses of drugs or devices.

Ronald N. Jones, MD, has received grant/research support from AB Biodisk, Abbott Laboratories, AlamX, Arpida, AstraZeneca Pharmaceuticals LP, Avexa, Basilea Pharmaceuticals, Bayer Pharmaceuticals, Becton Dickinson, BioMerieux, Bristol-Myers Squibb, Cadence Pharmaceuticals, Cerexa, Chiron Corporation, Cognigen, Cubist Pharmaceuticals, Daiichi, Elan Pharmaceuticals, Elanco, Enanta, GlaxoSmithKline, Intrabiotics, Johnson & Johnson, LG Chemicals, Merck & Co, Inc, Micrologix, Novartis Pharmaceuticals Corporation, Optimer, Ordway, Oscient Pharmaceuticals, Osmotics, Peninsula, Pfizer Inc, Replidyne, Inc, Schering-Plough Corporation, Sequoia, Serenex, Shionogi, Theravance, TREK Diagnostic Systems, Vicuron Pharmaceuticals, and Wyeth Pharmaceuticals. Dr. Jones has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.

George H. McCracken, Jr, MD, is on the advisory boards of GlaxoSmithKline and Sanofi-Aventis. Dr. McCracken has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.

John E. McGowan, Jr, MD, has received grant/research support from AstraZeneca Pharmaceuticals, LP, BioMerieux, Elan Pharmaceuticals, 3M Health Care, and Pfizer Inc; and is a consultant for Cubist Pharmaceuticals, Dade Behring Inc, Elan Pharmaceuticals, Johnson & Johnson, Merck & Co, Inc, Replidyne, Inc, and Wyeth Pharmaceuticals. Dr. McGowan has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.

Lawrence C. Parish, MD, is a consultant for CollaGenex Pharmaceuticals and Quinnova Pharmaceuticals. Dr. Parish has disclosed that he will not reference unlabeled/unapproved uses of drugs or devices.

Michael E. Pichichero, MD, has received grant/research support from Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, MedImmune, Inc, Sanofi-Aventis, and Sanofi Pasteur; and has received honoraria from Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi-Aventis, and Sanofi Pasteur.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.


This independent CE activity is supported by an educational grant from GlaxoSmithKline.
top

1783

 

 

Program Information

Faculty
Target Audience
Activity Goal
Learning Objectives
CME Information
Disclosure Information
Technical Requirements


Release Date: December 15, 2006.

Termination Date: December 15, 2007.

Estimated Time for Completion of All 7 Symposia: 3 hours.
Individual symposium times vary.



Recommend this page
Recommend this to a colleague


This independent CE activity is supported
by an educational grant from GlaxoSmithKline.




ABOUT US  |  CONTACT US  |  CONTRACT  |  DIRECTIONS  |  PRIVACY POLICY  |  RESOURCES
Copyright © 1997-2017, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988